Claims
- 1. A method for treating a cancer cachexia in mammals without treating the cancer which comprises administering to a mammal in need of treatment a pharmaceutically effective amount of a quinone derivative of the formula: ##STR31## wherein R.sup.1 and R.sup.2 independently represent a hydrogen atom, an alkyl group, an alkenyl group or an alkoxy group, or may bind together to form --CH.dbd.CH--CH.dbd.CH--; R.sup.3 represents a hydrogen atom, an alkyl group or an alkenyl group; R.sup.4 represents an optionally substituted nitrogen-containing heterocyclic group; R.sup.5 represents a hydrogen atom, an alkyl group, an optionally substituted hydroxy-alkyl group or an optionally esterified or amidated carboxyl group; Z represents a group represented by: ##STR32## R.sup.0 represents a hydrogen atom or an alkyl group; n represents an integer from 0 to 12; m represents an integer from 0 to 3; k represents an integer from 0 to 7; provided that when m is 2 or 3, each Z within the [ ] independently represents a group defined above for Z and each k within the [ ] independently represents an integer from 0 to 7, or a pharmaceutically acceptable salt thereof.
- 2. The method according to claim 1, wherein R.sup.1 and R.sup.2 independently are a hydrogen atom, a methyl group or an methoxy group.
- 3. The method according to claim 1, R.sup.3 is a hydrogen atom or a methyl group.
- 4. The method according to claim 1, wherein the sum of m and n is an integer from 0 to 10.
- 5. The method according to claim 1, wherein the nitrogen-containing heterocyclic ring group is a 5- or 6- membered heterocyclic group containing at least one nitrogen atom as a ring-forming atom.
- 6. The method according to claim 1, wherein R.sup.4 is a pyridyl group, an imidazolyl group or a thiazolyl group.
- 7. The method according to claim 1, wherein R.sup.4 is a pyridyl group and n is an integer from 0 to 10.
- 8. The method according to claim 1, wherein m and n are both 0 and R.sup.5 is a hydrogen atom or a methyl group.
- 9. The method according to claim 1, wherein the cancer cachexia originates from a carcinoma.
- 10. The method according to claim 1, wherein the cancer cachexia originates from a solid cancer.
- 11. The method according to claim 1, wherein the cancer cachexia originates from a colorectal cancer.
- 12. The method according to claim 1, wherein R.sup.1, R.sup.2 and R.sup.3 are an alkyl group, n and m are 0, and R.sup.5 is a hydrogen atom.
- 13. The method according to claim 12, wherein R.sup.4 is a pyridyl group.
- 14. A method for treating a cancer cachexia in mammals without treating the cancer which comprises administering to a mammal in need of treatment a pharmaceutically effective amount of 3,5,6-trimethyl-2-(3-pyridyl)methyl-1,4-benzoquinone hydrochloride.
- 15. A method for treating a cancer cachexia in mammals without treating the cancer, which comprises administering to a mammal in need of treatment a pharmaceutically effective amount of hydroquinone derivative of the formula: ##STR33## wherein R.sup.6 and R.sup.7 independently represent a hydrogen atom or a protective group; R.sup.1 and R.sup.2 independently represent a hydrogen atom, an alkyl group, an alkenyl group or an alkoxy group, or may bind together to form --CH.dbd.CH--CH.dbd.CH--; R.sup.3 represents a hydrogen atom, an alkyl group or an alkenyl group; R.sup.4 represents an optionally substituted nitrogen-containing heterocyclic group; R.sup.5 represents a hydrogen atom, an alkyl group, an optionally substituted hydroxy-alkyl group or an optionally esterified or amidated carboxyl group; Z represents a group represented by: ##STR34## R.sup.0 represents a hydrogen atom or an alkyl group; n represents an integer from 0 to 12; m represents an integer from 0 to 3; k represents an integer from 0 to 7; provided that when m is 2 or 3, each Z within the [ ] independently represents a group defined above for Z and each k within the [ ] independently represents an integer from 0 to 7, or a pharmaceutically acceptable salt thereof.
Priority Claims (1)
Number |
Date |
Country |
Kind |
6-190732 |
Aug 1994 |
JPX |
|
Parent Case Info
This application is a .sctn.371 application of PCT/JP95/01594, filed Aug. 10, 1995, which is a continuation of Japan 190732, filed Aug. 12, 1994.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/JP95/01594 |
8/10/1995 |
|
|
9/14/1995 |
9/14/1995 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO96/04909 |
2/22/1996 |
|
|
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4851413 |
Terao et al. |
Jul 1989 |
|
Foreign Referenced Citations (3)
Number |
Date |
Country |
0 234 729 |
Dec 1991 |
EPX |
WO9210498 |
Jun 1992 |
WOX |
WO9210190 |
Jun 1992 |
WOX |
Non-Patent Literature Citations (4)
Entry |
Ohkawa et al., The Journal of Medicinal Chemistry, vol. 34, No. 1, 1991, pp. 267-276. |
Willette et al., Pharmacology Communications, vol. 1, No. 4, 1992, pp. 329-335. |
Dinarello et al., Annals of the New York Academy of Sciences, vol. 587, 1990, pp. 332-338. |
Cryan et al., Prostaglandins Leukotrienes and Essential Fatty Acids (1990) 39 (4) pp. 311-317. |